| 9m | Blood sample, Urine for HCMV MV (n = 82) |
Blood sample, Urine for HCMV MV+DTP3 (n = 90) |
Blood sample, Urine for HCMV DTP3 (n = 53) |
||||||
| HCMV– | HCMV+ | HCMV– | HCMV+ | HCMV– | HCMV+ | ||||
| M | 22 (47.8%) |
24 (52.2%) |
M | 12 (26.7%) |
33 (73.3%) |
M | 7 (26.9%) |
19 (73.1%) |
|
| F | 11 (30.6%) |
25 (69.4%) |
F | 13 (28.9%) |
32 (71.1%) |
F | 7 (25.9%) |
20 (74.1%) |
|
| All | 33 (40.2%) |
49 (59.8%) |
All | 25 (27.8%) |
65 (72.2%) |
All | 14 (26.4%) |
39 (73.6%) |
|
| 10m | Blood sample, Urine for HCMV | Blood sample, Urine for HCMV | Blood sample, Urine for HCMV | ||||||
| HCMV– | HCMV+ | HCMV– | HCMV+ | HCMV– | HCMV+ | ||||
| M | 8 (17.4%) |
38 (82.6%) |
M | 3 (6.7%) |
42 (93.3%) |
M | 4 (15.4%) |
22 (84.6%) |
|
| F | 4 (12.5%) |
32 (87.5%) |
F | 6 (13.3%) |
39 (86.7%) |
F | 1 (3.9%) |
26 (96.1%) |
|
| All | 12 (14.6%) |
70 (85.4%) |
All | 9 (10%) |
81 (90%) |
All | 5 (9.4%) |
48 (90.6%) |
|
Infants were recruited at 4 months of age and randomized to one of the 3 vaccine groups: The MV group received their normal 4 month vaccines and MV alone at 9 months; the other 2 groups had DTP3 delayed and either given with MV at 9 months (MV+DTP group) or given alone (DTP group). All infants received their recommended vaccines from birth. At 9 and 10 months of age blood samples were taken for antibody and cellular assays and urine tested for HCMV by PCR. The number of HCMV+ and HCMV- infants at 9 and 10 months are shown by sex and the percentage values indicate the percent HCMV- or HCMV+ in that vaccine group for males (M), females (F) or all infants combined (All). BCG, bacille Calmette-Guérin vaccine; OPV, oral polio vaccine; HBV, hepatitis B vaccine; DTP, diphtheria-tetanus-whole cell pertussis vaccine; Hib, Haemophilus influenzae type b vaccine. The bold letters indicate the vaccine interventions in the study protocol.